Pillsbury advised Chase Therapeutics Corporation, a Washington, DC based clinical stage pharmaceutical company, in the completion of a milestone-based $20 million Series B financing led by Chinalink Asia Holdings of Hong Kong. This round builds on the earlier financings from Brain Trust Accelerator Fund II of Burlingame, California, and the Rise of the Rest Fund and Makana Holdings of Washington, DC.

The proceeds of the Series B will support Phase 3 pivotal trials for CTC-501 for the treatment of Major Depressive Disorder and CTC-413 for the treatment of Parkinson’s Disease as well as completion of the development and validation of a diagnostic product for Parkinson’s Disease.

The Pillsbury team included Corporate partner Steven Meltzer, counsel Alyssa Fiedler, and associates Patrick Dolan and Robert Shoemaker.